Karyopharm Therapeutics KPT-9274 had its Phase Transition Success Rate (PTSR) plummet in multiple oncology indications due to the termination of a Phase I basket trial recruiting patients with solid tumours and non-Hodgkin’s lymphoma (NHL). KPT-9274’s PTSR dropped by 21 points in melanoma to 11% and 14 points to 8% in colon cancer. It also dived by 18 points and 21 points in NHL and sarcomas, respectively, to 14% and 11%.

The Phase I PANAMA trial’s (NCT02702492) status was updated on 25 June from recruiting to sponsor-decided termination. The PTSR was updated on 29 June. PTSR is the probability, given as a percentage, of a drug progressing successfully from one development stage to the next.

KPT-9274 is a dual inhibitor of PAK4 (p21 activated kinase) and NAMPT (nicotinamide phosphoribosyltransferase), with this inhibition approach designed to trigger cancer cell apoptosis. PANAMA was primarily investigating for KPT-9274 maximum tolerated dose as a monotherapy and in combination with either niacin or Bristol Myers Squibb’s Opdivo (nivolumab).

KPT-9274’s Likelihood of Approval (LoA) also declined on the back of the PANAMA trial’s termination, ranging from 6 points to 4% in NHL to 1 point to 0% in colon cancer. LoA is identified via GlobalData’s analysis using a combination of machine learning and its proprietary algorithm.

Karyopharm has a market cap of $775m.

Reynald Castaneda is an Associate Editor for Clinical Trials Arena parent company GlobalData’s investigative journalism team. A version of this article originally appeared on the Insights module of GlobalData’s Pharmaceutical Intelligence Center. To access more articles like this, visit GlobalData.